Clinical Trial Update: Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis [EARLY_Phase 1]

View source ↗

Summary

An early-phase study evaluating whether Rocatinlimab (AMG 451) alters the pharmacokinetics of multiple cytochrome P450 substrates in adults with moderate-to-sev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Rocatinlimab (rocatinlimab)

Snippet

Sponsor: Amgen | Conditions: Atopic Dermatitis | EARLY_Phase 1 | Status: COMPLETED